#1 Clinical Trials Search in Europe

Pirfenidone

Pirfenidone is an antifibrotic drug that has shown promise in treating various conditions characterized by tissue scarring and fibrosis. This article summarizes key findings from clinical trials investigating pirfenidone’s efficacy and safety for conditions like idiopathic pulmonary fibrosis, chronic kidney disease, and other fibrotic disorders. We’ll explore how this medication is being studied to potentially slow disease progression and improve outcomes for patients with these challenging conditions.

Table of Contents

Introduction

Pirfenidone is a medication that has shown promise in treating various lung conditions characterized by scarring (fibrosis) of lung tissue. This article will provide an overview of pirfenidone, including what it is used for, how it works, and what patients can expect when taking this medication.[1][2]

What is Pirfenidone?

Pirfenidone is an oral medication used to treat certain types of lung fibrosis. It is also known by the brand name Esbriet.[1] Pirfenidone works by reducing inflammation and slowing down the scarring process in the lungs.[3]

Conditions Treated with Pirfenidone

Pirfenidone is primarily used to treat the following conditions:

  • Idiopathic Pulmonary Fibrosis (IPF): A chronic, progressive lung disease characterized by scarring of lung tissue.[2]
  • Coal Workers’ Pneumoconiosis (CWP): Also known as “black lung,” this is a lung disease caused by long-term exposure to coal dust.[1]
  • Chronic Hypersensitivity Pneumonitis (HP): An inflammatory lung disease caused by repeated inhalation of certain substances.[4]
  • Hermansky-Pudlak Syndrome (HPS) related Interstitial Lung Disease (ILD): A rare genetic disorder that can lead to lung scarring.[5]

How Pirfenidone Works

Pirfenidone has both anti-inflammatory and anti-fibrotic properties. It works by:

  • Reducing the production of inflammatory substances in the body
  • Slowing down the formation of scar tissue in the lungs
  • Modulating the activity of certain proteins involved in the fibrosis process, such as TGF-beta and MMPs[4]

Dosage and Administration

Pirfenidone is typically taken orally in capsule form. The usual dosage is as follows:

  • Starting dose: 267 mg three times a day for 1 week
  • Second week: 534 mg three times a day
  • Maintenance dose: 801 mg three times a day[1]

It’s important to take pirfenidone with food to reduce the risk of stomach-related side effects. Your doctor may adjust the dosage based on your individual response and tolerance to the medication.

Effectiveness of Pirfenidone

Clinical trials have shown that pirfenidone can be effective in slowing down the progression of lung fibrosis. Specifically, it has been found to:

  • Reduce the decline in lung function, as measured by Forced Vital Capacity (FVC)[3]
  • Improve or stabilize the distance patients can walk in 6 minutes (6-minute walk test)[3]
  • Potentially reduce the risk of respiratory-related hospitalizations[1]

Potential Side Effects

Like all medications, pirfenidone can cause side effects. Common side effects may include:

  • Nausea and stomach discomfort
  • Skin reactions, such as rash or increased sensitivity to sunlight
  • Fatigue
  • Headache
  • Dizziness[2]

It’s important to discuss any side effects with your healthcare provider. They can help manage these effects or adjust your treatment if necessary.

Ongoing Research

Research on pirfenidone is ongoing, with several clinical trials exploring its use in various lung conditions. Some areas of current research include:

  • Long-term safety and effectiveness in real-world settings[2]
  • Use in coal workers’ pneumoconiosis[1]
  • Effectiveness in chronic hypersensitivity pneumonitis[4]
  • Treatment of lung disease associated with Hermansky-Pudlak Syndrome[5]

Frequently Asked Questions

How long does it take for pirfenidone to start working?

Pirfenidone works gradually to slow down lung fibrosis. It may take several months before you notice improvements in your symptoms or lung function tests. Your doctor will monitor your progress regularly.

Can I stop taking pirfenidone if I feel better?

No, you should not stop taking pirfenidone without consulting your doctor. Pirfenidone is typically a long-term treatment, and stopping it abruptly may lead to worsening of your condition.

Are there any lifestyle changes I should make while taking pirfenidone?

Yes, it’s important to avoid or limit sun exposure while taking pirfenidone, as it can increase your skin’s sensitivity to sunlight. You should also quit smoking if you currently smoke, as this can worsen lung fibrosis.

Summary

Aspect Details
Generic Name Pirfenidone
Brand Name Esbriet
Main Uses Idiopathic Pulmonary Fibrosis, Coal Workers’ Pneumoconiosis, Chronic Hypersensitivity Pneumonitis
How It Works Anti-inflammatory and anti-fibrotic properties
Typical Dosage 801 mg three times daily (after titration period)
Common Side Effects Nausea, skin reactions, fatigue, headache
Ongoing Research Long-term safety, effectiveness in various lung conditions

Glossary

  • Fibrosis – The formation of excess fibrous connective tissue in an organ or tissue, often as a result of injury or chronic inflammation
  • Idiopathic Pulmonary Fibrosis (IPF) – A chronic lung disease of unknown cause, characterized by progressive scarring of lung tissue
  • Coal Workers’ Pneumoconiosis (CWP) – A lung disease caused by long-term inhalation of coal dust, also known as “black lung”
  • Hypersensitivity Pneumonitis (HP) – An inflammatory lung condition caused by an immune system reaction to inhaled substances
  • Interstitial Lung Disease (ILD) – A group of disorders characterized by inflammation and scarring of lung tissue
  • Forced Vital Capacity (FVC) – The total amount of air exhaled during a forced breath, used as a measure of lung function

Trial Sources

  • [1]: https://clinicaltrials.gov/study/NCT04461587
  • [2]: https://clinicaltrials.gov/study/NCT02699879
  • [3]: https://clinicaltrials.gov/study/NCT03208933
  • [4]: https://clinicaltrials.gov/study/NCT02496182
  • [5]: https://clinicaltrials.gov/study/NCT04193592
Condition Key Findings Dosing Outcomes Measured
Idiopathic Pulmonary Fibrosis Slowed decline in lung function, improved progression-free survival 2403 mg/day in divided doses FVC change, survival, quality of life
Chronic Kidney Disease Potential to slow progression of renal damage 2400 mg/day in divided doses Renal function markers, disease progression
Interstitial Lung Disease in Dermatomyositis May improve survival in rapidly progressive cases 1800 mg/day in divided doses 12-month survival, lung imaging changes
Lung Transplant Rejection Being studied for restrictive chronic lung allograft dysfunction 2403 mg/day after titration FVC change, CT scan findings, tolerability
Neurofibromatosis Type 1 Investigated for plexiform neurofibroma growth 500 mg/m2 three times daily Tumor volume, quality of life, safety

FAQ

  • What is pirfenidone and how does it work? Pirfenidone is an oral antifibrotic medication that inhibits the production of growth factors involved in fibrosis, including fibroblast growth factor, epidermal growth factor, and platelet-derived growth factor. It helps reduce inflammation and slow the buildup of scar tissue in organs like the lungs and kidneys.
  • What conditions is pirfenidone being studied for in clinical trials? Clinical trials are investigating pirfenidone for conditions like idiopathic pulmonary fibrosis, chronic kidney disease, interstitial lung disease associated with connective tissue disorders, lung transplant rejection, and plexiform neurofibromas in neurofibromatosis type 1.
  • What are some of the key outcomes being measured in pirfenidone trials? Common outcomes include changes in lung function tests like forced vital capacity (FVC), progression of fibrosis on imaging, quality of life measures, survival rates, and safety/tolerability of the medication when used long-term or in combination with other treatments.
  • How is pirfenidone typically administered in clinical trials? Pirfenidone is usually given orally in divided doses, often titrated up to a full dose over several weeks. For example, some trials use a target dose of 2403 mg per day, given as 801 mg three times daily.
  • What are some of the potential side effects of pirfenidone being monitored? Common side effects monitored include gastrointestinal symptoms, skin reactions, and liver enzyme abnormalities. Trials are assessing the overall tolerability and tracking any serious adverse events that may occur with long-term use.

Ongoing Clinical Trials on Pirfenidone

  • Long-Term Safety Study of Inhaled Pirfenidone for Patients with Progressive or Idiopathic Pulmonary Fibrosis

    Recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Czechia France Germany Italy The Netherlands Poland +1

  • Study of Inhaled Pirfenidone for Patients with Progressive Pulmonary Fibrosis

    Recruiting

    1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany Italy The Netherlands Poland +1

  • Study on the Effects of Wharton’s Jelly Mesenchymal Stem Cells, Pirfenidone, and Nintedanib for Patients with Fibrotic Interstitial Lung Disease

    Recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Poland

  • A study to evaluate the effectiveness of upadacitinib and pirfenidone in reducing symptom severity in patients with Long Covid

    Not yet recruiting

    1 1 1
    Investigated drugs:
    Italy

  • Study on Pirfenidone for Preventing Lung Fibrosis in Patients with Acute Respiratory Distress Syndrome (ARDS)

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study on Pirfenidone Inhalation Solution for Patients with Progressive Fibrosing Interstitial Lung Diseases, Including Idiopathic Pulmonary Fibrosis

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Czechia The Netherlands Poland

  • Study on Idiopathic Pulmonary Fibrosis: Evaluating Pirfenidone and Nintedanib for Patients with Progressive Disease

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on the Effects of Deupirfenidone and Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Greece Romania

Glossary

  • Idiopathic Pulmonary Fibrosis (IPF): A chronic lung disease characterized by progressive scarring of lung tissue, leading to breathing difficulties. The cause is unknown.
  • Forced Vital Capacity (FVC): The total amount of air exhaled forcefully after taking a deep breath. It's an important measure of lung function used to assess conditions like pulmonary fibrosis.
  • Antifibrotic: A type of medication that helps prevent or reduce the formation of excess fibrous tissue (scarring) in organs and tissues.
  • Plexiform Neurofibroma: A benign nerve sheath tumor that can occur in patients with neurofibromatosis type 1. These tumors can cause disfigurement and other complications.
  • Chronic Kidney Disease (CKD): A condition characterized by gradual loss of kidney function over time, often due to damage and scarring of the kidneys.
  • Interstitial Lung Disease (ILD): A group of disorders that cause inflammation and scarring of lung tissue, leading to breathing difficulties.
  • Dermatomyositis: An inflammatory disease characterized by muscle weakness and skin rashes. It can sometimes be associated with interstitial lung disease.
  • Lung Allograft Dysfunction: A complication following lung transplantation where the transplanted lung does not function properly, often due to rejection or scarring.